Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 23c

Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights

August 5, 2021 4:05 PM EDT

$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021)
415 patient start forms (PSFs) received for LUPKYNIS during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date
Continued ex-U.S. execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka
Cash and cash equivalents, and investments of $323.7 million at June 30, 2021
Conference call to be hosted today at 4:30 p.m. EDT

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial... More